It seems like Medtronic is interested to continue investing in aortic and peripheral vascular business, since it has been among its fastest-growing divisions for the past five years. The company has already disclosed an investment in Arsenal AAA, a subsidiary of Arsenal Medical - which develops technology to avoid complications linked to endovascular aneurysm repair (EVAR) procedures.
A few days after the announcement of this investment, Medtronic revealed its acquisition of Aptus Endosystems – maker of two FDA-cleared fastening devices and a steerable catheter for delivery of peripheral vascular products, which Medtronic will distribute. This statement was made during the Society for Vascular Surgery’s annual meeting.
In a press release, the company said that these two investments were “demonstrations of Medtronic’s’ commitment to leadership in the Aortic space.” According to ReportsnReports.com, the market for aortic stent grafts is expected to increase at a compound annual growth rate of 6.7% until 2020, when it is expected to reach $1.9 billion. The market research company still states “Despite the high product price, physicians still see a significant benefit in providing endovascular options ahead of performing open surgery”.